Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 
24 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lemtrada (alemtuzumab) / Sanofi
2014-000709-10: Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis. Untersuchung, wie der Wirkstoff Alemtuzumab bei Patienten mit schubförmig remittierender multipler Sklerose wirkt.

Ongoing
4
15
Europe
Concentrate for solution for infusion, LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung
Universitätsklinikum Münster, Genzyme Corporation
relapsing-remitting multiple sclerosis schubförmig remittierende multiple Sklerose, relapsing-remitting multiple sclerosis schubförmig remittierende multiple Sklerose, Diseases [C] - Nervous System Diseases [C10]
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
ACTRN12608000435381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One

Active, not recruiting
3
581
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
ACTRN12608000426381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two

Active, not recruiting
3
700
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
2016-000464-42: The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab

Ongoing
3
100
Europe
Lemtrada, GZ402673, Concentrate for solution for infusion, Lemtrada
Genzyme GmbH, Genzyme GmbH
Relapsing-remitting multiple sclerosis, Relapsing-remitting multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
LemKids, NCT03368664 / 2016-003100-30: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Active, not recruiting
3
16
Europe, RoW
Alemtuzumab GZ402673, Lemtrada, Glatiramer acetate, Copaxone, Beta-Interferon, Methylprednisolone, Ranitidine, Ceterizine, Dexchlorpheniramine, Paracetamol, Acyclovir, Prednisolone, Diphenydramine, Other H1 antagonist
Genzyme, a Sanofi Company
Multiple Sclerosis
05/21
12/25
RAM-MS, NCT03477500 / 2017-001362-25: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS

Recruiting
3
100
Europe
Cyclophosphamide and ATG, Sendoxan, Alemtuzumab, Lemtrada, Cladribine Pill, Mavenclad, Ocrelizumab, Ocrevus
Haukeland University Hospital
Multiple Sclerosis
03/24
03/26
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
ACTRN12621001502820p: Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial.

Not yet recruiting
2/3
80
 
Griffith University, Brazil Family Foundation
Multiple Sclerosis
 
 
ACTRN12621001502820: Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial.

Recruiting
2/3
80
 
Griffith University, Brazil Family Foundation
Multiple Sclerosis
 
 
2005-002305-23: A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.

Ongoing
2
20
Europe
Alemtuzumab, MabCampath ®, MabCampath ®
R&D Addenbrookes Hospital
Relapsing Remitting Multiple Sclerosis
 
 
2016-001166-29: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST) Eine randomisierte kontrollierte Studie zum Vergleich von Ocrelizumab oder Alemtuzumab mit autologer hämatopoetischer Stammzelltransplantation (aHSCT) bei hoch entzündlicher Multipler Sklerose (COAST)

Not yet recruiting
2
50
Europe
alemtuzumab, ocrelizumab, autologous hematopoietic stem cells, aHSC, Solution for infusion, Lemtrada, Ocrevus
University Medical Centre Hamburg-Eppendorf, Neovii Pharmaceuticals AG
relapsing-remitting multiple sclerosis schubförmig remittierende Multiple Sklerose, multiple sclerosis with relapses that are followed by periods of partial or complete recovery Multiple Sklerose, die in einzelnen Schüben verläuft, welche sich vollständig oder unvollständig zurückbilden, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002654-95: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Nessuna evidenza di attività della malattia dopo trapianto autologo di cellule staminali ematopoietiche nella Sclerosi Multipla aggressiva

Not yet recruiting
2
90
Europe
OCREVUS, Kesimpta 20 mg soluzione iniettabile, TYSABRI, LEMTRADA, Non disponibile, Solution for injection, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, OCREVUS, Kesimpta, TYSABRI, LEMTRADA
FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS, Fondazione Italiana Sclerosi Multipla
Relapsing Remitting Multiple Sclerosis Sclerosi multipla recidivante remittente, A type of MS where you have relapses (symptoms getting worse) followed by recovery (that's when it's “remitting”) Forma di Sclerosi Multipla nella quale in cui si hanno ricadute (sintomi che peggiorano) seguite da guarigione (le remissioni)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03983252: Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Not yet recruiting
1/2
10
US
[F-18]PBR06, [18F]PBR06
Brigham and Women's Hospital, Genzyme, a Sanofi Company
Multiple Sclerosis
05/24
05/24
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
N/A
4000
NA
Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
University of British Columbia
Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
12/20
12/20
NCT05075499: Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Recruiting
N/A
70
RoW
COVID-19 vaccination, Blood withdrawn
Sheba Medical Center, Sanofi
Multiple Sclerosis
12/21
09/22
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT06310343: ADAs to Alemtuzumab

Active, not recruiting
N/A
15
Europe
Alemtuzumab
Queen Mary University of London
Multiple Sclerosis
11/25
11/25
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Active, not recruiting
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
12/22
12/22
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
NCT04633967: Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

Completed
N/A
30
Canada
Alemtuzumab Injection
Maritime Neurology
Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis
12/20
02/21

Download Options